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Abstract
Runs of homozygosity (ROH) represents extended length of homozygotes on a long genomic distance. In oncology, it is
known as loss of heterozygosity (LOH) if identified exclusively in cancer cell rather than in matched control cell. Studies have
identified several genomic regions which show consistent ROH in different kinds of carcinoma. To query whether this
consistency can be observed on broader spectrum, both in more cancer types and in wider genomic regions, we
investigated ROH patterns in the National Cancer Institute 60 cancer cell line panel (NCI-60) and HapMap Caucasian healthy
trio families. Using results from Affymetrix 500 K SNP arrays, we report a genome wide significant association of ROH
regions between the NCI-60 and HapMap samples, with much a higher level of ROH (11 fold) in the cancer cell lines. Analysis
shows that more severe ROH found in cancer cells appears to be the extension of existing ROH in healthy state. In the
HapMap trios, the adult subgroup had a slightly but significantly higher level (1.02 fold) of ROH than did the young
subgroup. For several ROH regions we observed the co-occurrence of fragile sites (FRAs). However, FRA on the genome
wide level does not show a clear relationship with ROH regions.
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Introduction
In diploid organisms, SNPs are categorized into heterozygotes
and homozygotes according to the difference/identity between
paternal and maternal alleles. Loss of heterozygosity (LOH) [1] in
a cell represents the conditions of loss of normal function of one
allele when the other allele was already inactivated. LOH may
cause tumor suppressor gene loss of function, which is associated
with oncogenesis [2].
Genomic regions affected by LOH often exhibit an extended
length of homozygous SNPs, which forms regions with low
diversity between two copies of DNA. Studies in E. coli [3],
Trypanosoma brucei [4] and mouse [5] show the importance of
extended sequence similarity/diversity in promoting/preventing
homologous recombination. This recombination, if happened
during mitotic process, maybe related to subsequent LOH [6] and
affects genome stability [7,8]. Study by Bacolod, M.D. [9] shows
that colorectal cancer patients have average length of identical by
descent region twice the length of healthy population. Based on
the colorectal cancer data, they later proposed a cancer gene
activity model (CGAM) [10] in an effort to explain how
autozygosity influences cancer predisposition. Similarly, a study
by Assie, G et al. [11] investigated breast, prostate, head and neck
carcinomas and found 16 common loci that have significantly
increased germline homozygosity frequency.
From these previous works, we conclude that 1) LOH is related
to diseases and 2) in cancer there may be an extension of germline
homozygous region. This has been shown population wise in some
type of cancer, and in certain loci across three different types of
carcinoma. Question remains if this phenomenon can be
extrapolated to multiple cancers at the whole genome scale. We
are hypothesizing that the increased size of the homozygous
regions in cancer arises from the extension of regions found in
germline. We are also hypothesizing that the genomic position of
homozygous regions are not equally distributed across the genome
(conserved across individuals) and therefore could depend on the
local properties of the genomic DNA. Finally, we are postulating
that homozygous regions in germline that are dramatically
extended in cancer could have the natural propensity to expend
upon aging. In this manuscript we will refer to these homozygous
regions as runs of homozygosity (ROH).
We have performed a genome wide comparison of ROH
position and length in cancer cell lines from the NCI-60 library as
well as in germline samples from young and adult individuals
obtained from 30 HapMap Caucasian trio families. We also
investigated if a proximity relationship exists between ROH
positions and fragile sites (FRA) that undergo more often DNA
damage repairs. In addition we investigated similar relationship
between ROH and microRNA (miRNA) sites that have been
shown to be associated to FRA regions [12].
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NCI-60 Cancer Cell Line and HapMap Samples
The NCI-60 was developed as an anticancer drug screen panel
by the US National Cancer Institute (NCI), Developmental
Therapeutics Program (DTP, http://dtp.nci.nih.gov/) [13]. It
contains 60 Caucasian tumor cell lines from brain (BR), central
nervous system (CNS), colon (CO), lung (LC), white blood cell
(LE), melanocyte (ME), ovary (OV), prostate (PR) and renal (RE).
Detailed information about NCI-60 is available at CellMiner
website (http://discover.nci.nih.gov). To prepare cell lines for
Affymetrix 500 K SNP array analysis, frozen stocks of the NCI-60
were obtained from the NCI Developmental Therapeutics
program (NCI DTP). The cells were cultured as described
previously [14], and then thawed, placed in RPMI 1640 (Lonza
Walkersville, Inc.) containing 5% fetal calf serum (Atlantic
Biologicals) and 2 mM glutamine (Invitrogen Corporation). For
compatibility with our other profiling studies, we used the same
batch of serum used by DTP, and the procedures were done or
overseen by the same researcher (WCR). The colon cell line HT29
was removed due to contamination. Results of two replicates on
ovary cell line OVCAR-3 were merged, and discrepant results
were set to unknown. After exclusion and merge, SNP array data
of 59 cancer cell lines were used in the final analysis. The NCI-60
Affymetrix 500 K SNP array data is publicly available from Gene
Expression Omnibus (GSE32264).
The International HapMap Project is a muti-country effort to
identify and catalog genetic similarities and differences in human
beings (http://HapMap.ncbi.nlm.nih.gov/). Only HapMap sam-
ples with European origin were used to minimize the ethnic
difference with the NCI-60 samples. A total of 59 cancer cell lines
and 30 normal HapMap CEU trio families (30 children (young)
+60 parents (adult)) genotyped with the Affymetrix 500 K SNP
array were analyzed. Genotype calls were made using Affymetrix
Power Tool (APT) (Linux, version 1.12.0) using the BRLMM
algorithm (http://media.affymetrix.com/support/technical/
whitepapers/brlmm_whitepaper.pdf) at the default confidence
level (,=0.5). The average ‘‘NoCall’’ rate is 4.2% in the NCI-
60 and 0.5% in HapMap samples.
Identify Runs of homozygosity (ROH), ROH frequency
(ROHF) and Hemizygous deletion frequency (HDF)
Existing studies primarily identify ROH by moving a fixed-size
window along SNP genotypes and detecting long stretch of
homozygotes. Drawbacks of this scheme are 1) there is no
standardized criteria for calling ROH, 2) different settings on
window size, homozygous SNP number, accommodation for
genotyping error, or homozygotes stretch length threshold may
significantly influence the result [15]. To avoid bias that may arise
from inappropriately chosen criteria, ROH in the current study
was primarily detected by basic Hidden-Markov Model (HMM)
procedure proposed by Beroukhim R. et al. [16]. While still
arbitrary, HMM is less sensitive to interspersed heterozygotes in
that it tracks the state change between low and high heterozygosity
rates. Although HMM was primarily used to detect LOH, its
working principle makes it applicable to ROH detection. By
locating the position where transition probability is higher than a
given threshold, HMM differentiates ROH from normal hetero-
zygosity regions. Basic-HMM procedure available in the dChip
software (Version 2010/01) [17] was used to perform the analysis
with default settings. SNPs annotations from Human genome
build 19 were used. In addition to HMM algorithm, we also used
PLINK (Version 1.07) (http://pngu.mgh.harvard.edu/purcell/
plink/) [18] (based on fixed size window) as an alternative way
to detect ROH. The parameters used in PLINK are provided as
(Table S5).
ROH frequency (ROHF) is defined as the proportion of
samples with ROH for each SNP locus. To reduce background
noise in the ROHF calculation, ROHF in FRA regions is
calculated by taking mean values of the upper 95
th percentile
ROHF in the 65 Mb range.
Copy number variation was computed by pennCNV [19],
which provides integer copy number estimate. The copy number
information was used to calculate hemizygous deletion frequency
(HDF) that is defined as the proportion of samples with only 1
copy of allele for each SNP locus. The average number of SNP
with hemizygous deletion is about 25,000 (5% SNPs on 500 K
array). The maximum HDF is 0.24 in the NCI-60 cell lines.
miRNA and FRA database
Information on 1049 miRNA was obtained from miRBase
www.miRNAbase.org (Version 16) [20]. After excluding records
located on chromosome X and Y, 955 miRNA records were
involved in current analysis. FRA information was obtained from
the HUGO Gene Nomenclature Committee (HGNC) www.
genenames.org/cgi-bin/hgnc_stats.pl (Last Update 09/11/10).
Totally 111 FRAs located on autosomes were involved in current
analysis. Since only FRAs’ cytogenetic position is available, we
converted these positions in genomic coordinates as follow. A
database covered 42,574 gene records (obtained from NCBI
Entrez Gene database) with both cytogenetic and genomic
location was used to map the genomic location of FRAs. As a
result, minimum genomic start and maximum genomic end
positions were used to represent the FRA region, and the mean
value was used to represent the FRA location (As indicated on the
4
th bar in Figure 1). For each FRA, we considered, based on a
recombination rate less than 0.5, that 65 Mb can be used as a
maximum distance in our search for FRA related genomic
changes. We also reduced the region down to 61 Mb when
analyzing miRNA-FRA relationship.
Statistical Analysis
ROHF correlation coefficients (Table 1 12
th column) between
NCI-60 and HapMap samples were obtained after adjusting for
SNP density and HDF. Correlation P values were further adjusted
by Bonferroni correction.
Adult and young subgroups are different in sample size
(Nadult=60, Nyoung=30), thus direct comparison on their ROHF
would be inappropriate (consider SNPs where only one adult and
zero young has ROH). To eliminate the bias, we shrunk the
number of adults to 30 individuals by non-redundant re-sampling.
1000 random adult datasets were generated. ROHF was
calculated for each dataset. For each locus the mean value was
used to represent the adult ROHF, which was compared with
young ROHF to determine statistical significance (Student t-test
followed by Bonferroni correction). The null hypothesis is that
there is no significant difference in ROHF between adult and
young. To estimate the power of the test, we also calculated the
proportion of datasets with positive ROHFdiff (=ROHFadult
2ROHFyoung) among datasets that show significant difference
between adult and young.
Pathway analysis was conducted by selecting the SNPs with
ROHF difference ranked top 5000 (ROHFdiff=0.59), 10000
(0.54), 15000 (0.51), 20000 (0.49), and 25000 (0.47) between NCI-
60 and HapMap sample, as well as between HapMap adult and
young subgroups. SNPs selected by applying these different cutoff
settings were analyzed with the GeneGO web tool (GeneGO Inc.)
to report pathways enriched in significant SNPs.
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chromosome X and Y were excluded from current analysis. All
analyses were conducted by using R version 2.10.0 in the Unix
environment.
Results
ROH in the NCI-60 and HapMap samples
Figure 1 illustrates ROHF among the NCI-60 and HapMap
samples, as well as the physical locations of miRNA and FRA sites.
The average ROHF is 0.32 for the NCI-60, and 0.03 for the
HapMap samples (Table 1). Generally, we observe massive ROH
events spread across the whole genome for the NCI-60 cell lines.
Chromosomes 9p, 13q, and 17p have the highest levels of ROH,
with average ROHF being 0.60, 0.51, and 0.57, respectively. The
same chromosome regions with increased ROHF in the NCI-60
were found to occur in the HapMap non-cancerous samples but
with lower ROHF (Figure 1). Significant correlations between the
NCI-60 and HapMap ROHF were found on all chromosomes
before and after adjustment for SNP density and HDF (Table 1,
12
th column). Similar patterns were observed using PLINK to
compute ROH (data not shown). We also analyzed the HapMap
CEPH Affymetrix 100 K array data and found ROHF pattern
same as that from 500 K array (Data not shown), indicating that
the observed patterns are independent of platform used for
genotyping as well as of the application used to compute ROHs.
Suspecting that regions with higher level of ROHF in healthy state
have stronger ROHF correlation between NCI-60 and HapMap
samples, we applied a stepwise increasing cutoff on SNPs
according to their ROHF levels in HapMap samples. The results
show a stepwise increase in correlation coefficient from 0.34 to 0.5
as the cutoff increases from .0.1 to .0.95 quantile (Figure S1).
This indicates that regions with existing ROH in healthy state are
more likely to have a higher level of ROHF in cancer cells. We
also analyzed the HapMap trios according to their status as adult
or young (detailed age information is not available, so only adult/
Table 1. Average ROHF on all chromosomes in NCI60 and HapMap samples.
NCI60 HapMap
Chr p+q
a p q FRA corr
b p(FRA corr) p+q p q FRA corr p(FRA corr) Corr
c SNP number
1 0.27 0.31 0.24 0.14 0.00E+00 0.04 0.03 0.04 0.07 0.0E+00 0.33 40200
2 0.18 0.14 0.20 0.00 7.30E-01 0.04 0.03 0.05 0.02 1.0E+00 0.73 41376
3 0.30 0.35 0.24 20.02 1.50E-04 0.03 0.03 0.03 20.17 1.2E-217 0.44 33761
4 0.36 0.34 0.36 20.08 1.39E-43 0.04 0.04 0.04 20.03 3.4E-04 0.72 32321
5 0.27 0.23 0.28 0.24 0.00E+00 0.03 0.03 0.03 0.21 0.0E+00 0.65 32039
6 0.30 0.20 0.36 20.17 6.26E-204 0.04 0.04 0.03 20.01 1.0E+00 0.31 31384
7 0.20 0.17 0.22 20.06 3.45E-23 0.03 0.02 0.03 0.02 1.0E+00 0.65 25790
8 0.31 0.36 0.28 20.25 0.00E+00 0.05 0.04 0.05 20.22 1.0E-293 0.56 27446
9 0.49 0.60 0.42 20.19 1.47E-190 0.03 0.03 0.03 20.01 1.0E+00 0.20 22862
10 0.43 0.43 0.43 20.01 3.52E-02 0.04 0.03 0.05 0.04 1.3E-09 0.66 28476
11 0.37 0.35 0.38 20.28 0.00E+00 0.04 0.05 0.04 20.03 2.2E-03 0.43 26241
12 0.26 0.28 0.25 20.04 1.58E-08 0.03 0.03 0.04 0.14 0.0E+00 0.51 24925
13 0.51 NA
d 0.51 0.18 0.00E+00 0.03 NA 0.03 0.22 0.0E+00 0.44 19106
14 0.40 NA 0.40 0.30 0.00E+00 0.03 NA 0.03 0.38 0.0E+00 0.81 15712
15 0.26 NA 0.26 20.03 3.48E-04 0.03 NA 0.03 20.01 1.0E+00 0.74 14339
16 0.30 0.27 0.31 20.02 2.91E-03 0.03 0.02 0.03 0.01 1.0E+00 0.87 15269
17 0.44 0.57 0.39 0.29 0.00E+00 0.02 0.01 0.03 0.08 0.0E+00 0.20 11255
18 0.34 0.24 0.37 0.45 0.00E+00 0.03 0.00 0.03 0.28 0.0E+00 0.56 14873
19 0.34 0.35 0.33 20.15 2.01E-32 0.02 0.04 0.02 20.20 7.5E-54 0.79 6394
20 0.18 0.22 0.15 0.41 0.00E+00 0.03 0.03 0.03 20.01 1.0E+00 0.43 12398
21 0.29 0.18 0.29 NA NA 0.02 0.00 0.02 NA NA 0.78 7113
22 0.43 NA 0.43 0.37 0.00E+00 0.01 NA 0.01 0.23 0.0E+00 0.48 6161
All
e 0.32 0.30 0.32 20.02 2.2E-16 0.03 0.03 0.04 0.02 2.2E-16 0.33 489441
ap and q stands for short and long arm, respectively.
bPearson correlation between ROHF and FRA(±5M ) .
cPearson correlation between the NCI-60 and HapMap ROHF, all p values less than 1e-10 after controlling for SNP density.
dNo SNP coverage on Affymetrix 500 k array.
eChromosome X and Y were excluded from analysis.
doi:10.1371/journal.pone.0031628.t001
Figure 1. NCI-60 and HapMap ROH pattern, and miRNA, FRA position. Red arrows on the right indicate the FRAs with average upper 95
th
percentile ROHF larger than 0.5 in a 65 Mb vicinity. Red asterisks indicate high ROHF bands (average upper 95
th percentile ROHF.0.6) without FRA
in 65 Mb vicinity. Rare FRAs are marked by red color. The gaps between the sections of the chromosomes (for example at 130 Mb nucleotides in
chromosome 1) contain the centromere. The top portion corresponds to p arm, and bottom portion corresponds to q arm.
doi:10.1371/journal.pone.0031628.g001
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showed significant ROHF differences between adult and young
subgroups (p,1.1e-10 after Bonferroni adjustment) with an
average of 0.06% higher ROHF in adult subgroup over the
whole genome (3.36% in young, 3.42% in adults). Among the
1000 randomly generated adult datasets (following numbers in
parenthesis are by PLINK deduction), 662 (833) have ROHFdiff
.0 and 747 (743) have P,10
27 (P,0.05 after Bonferroni
adjustment, two-tailed student t test). Among the 747 (743)
datasets with significance, 552 (686) have ROHFdiff.0. This
equals to a proportion of 73.9% (92.3%).
ROHF and FRAs
We did not observe a clear relationship between FRA and
ROHF on the whole genome scale, They exhibit negative
correlation in the NCI-60, and positive correlation in the HapMap
samples. Their correlations on different chromosomes also show
different directions (Table 1). Despite of this unclear relationship,
we indeed observed the co-occurence of several high ROHF bands
with FRAs. Among the 111 recognized FRAs, there are 30 bands
with an average upper 95
th percentile ROHF higher than 0.5 (1.64
standard deviation above mean ROHF) in the vicinity of FRAs
(Table 2, 4
th column). For these FRAs we see clear ROH bands
among the HapMap samples, and also among the NCI-60 samples
(with higher ROHFs) at the same physical location. Moreover, 4
FRAs have at least 0.5 ROHF difference between the NCI-60 and
HapMap samples (Table 2, 6
th column, shown in red). Due to the
computational similarity between ROH and LOH, we compared
the ROHF with previously reported LOH frequency around
FRAs. For FRA16D [21,22], FRA7G [23] and several other FRAs
that were previously reported to have LOH in close vicinity,
similar findings were also observed in our data. Cell line specific
analysis showed 50% ROHF in renal cancer cell lines at FRA3B,
and 57.1% in ovarian at FRA6E, which is close to the reported
value of 69% in renal cell carcinoma for FRA3B [24], and 72% in
ovarian cancer for FRA6E [25].
Table 2. Average upper 95th percentile ROHF and number of miRNA genes around FRAs.
FRA Chr CytoPos
a
ROHF
NCI-60
b
ROHF
HapMap
b
ROHF
(NCI-60-HapMap)
Num
miRNA (5 M)
c
Num
miRNA (1 M)
c
FRA1C 1 1p31.2 0.56 0.28 0.28 5 0
FRA2F 2 2q21.3 0.57 0.52 0.05 3 1
FRA4C 4 4q31.1 0.55 0.15 0.40 2 0
FRA5C 5 5q31.1 0.53 0.36 0.17 4 1
FRA5F 5 5q21 0.53 0.34 0.19 5 0
FRA7G 7 7q31.2 0.56 0.47 0.09 1 0
FRA9B 9 9q32 0.51 0.09 0.42 3 0
FRA9E 9 9q32 0.51 0.09 0.42 3 0
FRA9A 9 9p21 0.75 0.24 0.51 20
FRA9C 9 9p21 0.75 0.24 0.51 20
FRA10C 10 10q21 0.54 0.22 0.31 2 0
FRA10D 10 10q22.1 0.56 0.27 0.29 2 0
FRA10A 10 10q23.3 0.59 0.28 0.31 3 0
FRA11B 11 11q23.3 0.58 0.27 0.31 3 0
FRA11F 11 11q14.2 0.58 0.27 0.31 2 0
FRA11G 11 11q23.3 0.58 0.27 0.31 3 0
FRA12B 12 12q21.3 0.59 0.37 0.21 0 0
FRA13A 13 13q13.2 0.56 0.11 0.45 0 0
FRA13B 13 13q21 0.58 0.10 0.48 0 0
FRA13D 13 13q32 0.59 0.10 0.49 9 0
FRA13C 13 13q21.2 0.67 0.17 0.50 10
FRA14B 14 14q23 0.71 0.47 0.24 2 0
FRA14C 14 14q24.1 0.74 0.65 0.10 2 0
FRA16B 16 16q22.1 0.57 0.29 0.27 5 1
FRA16C 16 16q22.1 0.57 0.29 0.27 5 1
FRA17A 17 17p12 0.61 0.06 0.55 50
FRA17B 17 17q23.1 0.65 0.30 0.36 6 3
FRA18A 18 18q12.2 0.55 0.28 0.27 4 1
FRA22B 22 22q12.2 0.54 0.18 0.36 7 2
FRA22A 22 22q13 0.56 0.07 0.49 8 1
aCytogenetic position.
bAverage upper 95th percentile ROHF values in corresponding FRA region (Start and end position available in Table S2).
cNumber of miRNA genes within ±5 Mbs and ±1 Mbs range of FRAs.
doi:10.1371/journal.pone.0031628.t002
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vicinity. Table 3 shows a total of eight top ROH bands with
average top 95
th percentile ROHF ranging from 0.551 to 0.879
but no recognized FRAs nearby. The bands are also marked with
red asterisk in Figure 1. Two of these ROH bands are located at
the chromosome 16 centromere. A list of genes located in these
ROH bands is available in Table S1. On the other hand, we
observed that 81 out of 111 FRAs do not have associated
significant ROHF elevation in nearby regions (Table S2).
ROHF and miRNA
Calin G.A. et al. [12] proposed a possible association between
FRAs and miRNA location (incidence of 186 miRNA genes within
61 Mb of FRAs is 13 (ratio=0.07)). To obtain a comprehensive
view of the relationship among FRA, miRNA and ROH banding,
we incorporated the miRNA data in this study. Among 955
miRNAs investigated in our study, 63 were within 61 Mb range
of FRA locations (ratio=0.066). This number increased to 334
after expanding to 65 Mb range (ratio=0.35). Pearson correla-
tion analysis shows no association between miRNA location
(61 M range) and ROHF levels (Figure 1, p.0.05 after
bonferroni correction). In addition, we investigated the co-
occurrence of miRNA and FRA with ROHF elevation. In the
65 Mb vicinity of FRAs with ROHFs higher than 0.5, the
average number of miRNAs is 3.30. This number is 2.94 for FRAs
with nearby ROHFs lower than 0.5.
Pathway Analysis
We analyzed the SNPs with the top ROHF differences (See
statistical analysis section for detail) between adult and young
subgroups, as well as between the NCI-60 and HapMap samples
(Figure S2). For the adult versus young subgroup, the top ranked
process is the chemotaxis process (Figure 2). The genes present in
this category are marked with solid red circles in Figure 2, and
tabulated in Table S3. For the NCI-60 versus the HapMap
samples, the top ranked process is G1_S cell cycle process (Figure
S3 and Table S4), which indicates a change in several known
oncogenes such as P53 and LATS2. For these two genes we see
ROHF elevations as high as 61% and 50% in the NCI-60 as
compared to HapMap samples.
Discussion
Studies in prokaryotes and eukaryotes [3–5] show that high
similarity genomic regions may induce homologous recombina-
tion, which was proposed as a cause of LOH in mammalian cell
[6] and has complex role in genomic stability [7,8]. In this study,
we interrogated the sequence similarity by detecting the ROH
status on 500 K array through basic-HMM model as well as
PLINK ROH module. Analysis on NCI-60 cancer cell lines and
HapMap trios show highly similar ROH patterns (Figure 1),
which differ only in strength. The current finding indicates that
the massive ROH observed in cancer cells might be an extension
of the lower levels ROH observed in healthy cells. We consider
the current finding has wide applicability for several reasons.
First, the present study is based on 60 different cancer cell lines,
which excluded the potential bias caused by the unique genetic
construct of a specific type of cancer. Second, rather than using
patient-matched control (germ-line) DNA samples obtained from
non-tumor tissue, the cases and controls are totally un-matched.
Thus their similarity in ROH pattern is not due to the presence
of the same genetic background, and may reflect a more general
condition of human genome. Finally, the NCI-60 cell lines used
for the current SNP array analysis have passage number below
30 [26]. This should minimize the potential effect of culture-
induced genomic alteration [27]. On the other hand, we
observed that adult subgroup has higher level of ROH than
those of young in HapMap Caucasian trios (p,1.1e-10 after the
stringent Bonferroni adjustment). Since 1) exactly the same
HMM model parameters are used to call ROH independently in
adult and young subgroups, and 2) it is groundless to hypothesize
that young should born with lower ROH level than adult, we
have to accept the alternative hypothesis and propose that an
ongoing ROH happened in adults from the time point of their
own zygotes formation to the zygotes formation of their child.
Worth mentioning is that cell lines rather than original
lymphocyte DNA were used in the HapMap SNP array analysis.
Thus one can’t rule out that the observed difference could be
caused by culture-induced mutation or different passage number.
However, the current observation is in agreement with reported
higher level of LOH in old cells in model organisms [28]. Similar
observation was also done in human by Moragoda et al. [29] who
described age-associated stomach mucosa LOH among healthy
people over 60 year of age. Nevertheless, further investigations
are required to elucidate whether the ROH level difference
observed in our study is resulted from aging, disease, or
epigenetic factors.
Our data show some co-occurrence of FRAs and high ROHF
band in the same genomic region. This observation is in
agreement with previous findings done in some genomics regions
[21,23]. It was proposed that the AT-rich nature of FRA
sequences might confer them a highly variable nature [30–32].
For some FRAs, our data did not reproduce the high ROHF band
as indicated in historical studies on single caner type. A possible
explanation is that the ability of FRAs to induce ROH is different
across cancer types. Since the inter-tissue ROH similarity heatmap
shows a unique pattern of ROH in several cancer tissue types
(Figure S4), thus probably only FRAs that can induce ROH across
different cell lines will show association with high ROHF.
However, no clear correlation could be observed at the genome-
wide level between FRAs and high ROHF. This suggests that
although FRAs can play a role in ROH formation, it is not the
only cause of ROH formation. More interestingly, when
comparing the NCI-60 to HapMap samples, the difference of
ROHF was found lower in FRA regions than in non-FRA regions.
Table 3. High ROHF bands without FRA in within 65 Mb.
Chromosome Position
a Start (Mb)
b End (Mb)
b ROHF
c
1p 36030321 35 37 0.608
2p 83276616 82 85 0.551
3p 51216578 50 53 0.666
4p 33354084 32 36 0.726
11p 38675473 37 41 0.561
15q 43729998 42 46 0.66
16p 34923039 34 36 0.879
16q 47735030 46 49 0.755
aPhysical position of SNP locus with maximum ROHF in the range. The
middle one was used if multiple SNP loci have equal maximum value.
bApproximate start and end position in Mega base pair.
cAverage upper 95th percentile ROHF in ±5 Mb vicinity around
‘‘Position’’.
doi:10.1371/journal.pone.0031628.t003
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current FRA database, or might suggest that FRAs could protect
against ROH. In the latter case the FRA may function as a repair
spot for restoration of accidentally mis-segregated chromatid
during mitosis.
Pathway analysis on SNPs with higher ROHF in the adult
versus young subgroups implicates a change in chemotaxis
related genes. The genes in which these SNPs occur are marked
with solid red circles in Figure 2. Currently it is not clear how
ROH may qualitatively/quantitatively influence these genes.
However, this observation is in consistent with a progression of
metastatic tumor cells towards higher chemotaxis ability [33–35],
which is correlated with their potential for invasion, intravasa-
tion, and metastasis and responsible for the attraction of
carcinoma cells to blood vessels. The majority of the genes
identified here, including but not limited to CCR1 [36], CCR2
[37], CCR3 [38], ENA78 [39], GPCR [40], GRO1 [41],
GRO2/GRO3 [42], IP10 [43], IL-8 [44], NAP-2 [45], PF-4 [46]
have been recently shown to associate with the progression of
various types of cancer. We postulate that these genes might
partly account for oncogenesis in the progression from low
ROHF in healthy cell to high ROHF in cancer state. On the
other hand, analysis of SNPs with high ROHF differences
between the NCI-60 and HapMap samples shows a change in
cell cycle and translation initiation related process, which might
result from the progression of normal cells to cancerous cells
towards autonomy and faster replication. Thus, these pathway
analysis results may present a series of alterations leading to
oncogenesis. However, additional evidence is still needed to fill
the gap between the changes of genes in chemotaxis and cell cycle
process, and the onset of oncogenesis.
The large number of ROH regions found in the NCI-60
cancer cell lines, and its significant association with the
HapMap samples suggests a vital association of the ROH
events with neoplastic progression. Importantly, the observation
of higher ROHF in adults than in young, and the involvement
of onco-related chemotaxis genes may provide a clue to
understand the higher cancer incidence rate among older
people. Together, these observations imply that the significant
increase homozygotes in cancer cells might be a progression
from changes started early in healthy state. Further investigation
on the causal relationship between ROH and cancer will have
to be conducted to shade light on the mechanisms leading to
high ROH.
Figure 2. Genes involved in chemotaxis. Pathway analysis on SNPs with top ROHF difference between adult and young subgroups show the
involvement of chemotaxis process. Red solid circles show genes covering SNPs with top change (see statistics section for details).
doi:10.1371/journal.pone.0031628.g002
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Figure S1 NCI-60/HapMap ROHF correlation at geno-
mic regions with different levels of HapMap ROHF. The
plot shows an increase in NCI-60/HapMap ROHF correlation
coefficient (left axis, from 0.34 to 0.5), and NCI-60 ROHF (right
axis, from 0.33 to 0.44) in genomic regions with increased levels of
ROHF (from .0.1 to .0.95 quantile) in HapMap samples.
(TIF)
Figure S2 Processes involved in SNPs with top ROHF
differences. Processes involved in SNPs with top ROHF
difference between a) adult and young subgroups, and b) the
NCI-60 and HapMap samples (see statistics section for details).
(TIF)
Figure S3 Cell cycle G1_S phase. Pathway analysis on SNPs
with top ROHF difference between NCI-60 and HapMap show
the involvement of Cell cycle G1_S phase. Red solid circles show
genes covering SNPs with top change (see statistics section for
details).
(TIF)
Figure S4 Pair wise ROH similarity. a) Intra tissue, b) Inter
cell line (clustering based on pair-wise ROH similarities), and c)
Inter tissue pair wise ROH similarity in the NCI-60 cancer cell
lines
(TIF)
Table S1 Genes in High ROHF bands without FRA in
±5 Mb vicinity (Regions identified in Table 3).
(XLS)
Table S2 Average upper 95th percentile ROHF and
number of miR genes around FRAs.
(XLS)
Table S3 Genes with ROHF elevation in parent involved
in chemotaxis process (Shown in Figure 2).
(XLS)
Table S4 Genes with high ROHF difference between
NCI-60 and HapMap involved in cell cycle G1_S process.
(XLS)
Table S5 PLINK ROH module parameters setting.
(XLS)
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